Chemotherapy and HER2 blockers (such trastuzumab and pertuzumab) are the usual treatment for HER2-positive breast cancer since they greatly enhance prognosis (von Minckwitz et al., 2017). This evidence concerns the gene ERBB2 and breast carcinoma.